From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial

Last Updated: Thursday, July 22, 2021

The incidence of epidermal growth factor receptor inhibitor (EGFRI)-induced papulopustular rash ranges from 60% to 85%. This study found that prophylactic topical chloramphenicol 3% + prednisolone 0.5% (CHL-PRED) was more effective in treating EGFRI-induced rash than aqua cream.

Dermatology
Advertisement
News & Literature Highlights
Advertisement
Advertisement